CA3076566A1 - Lysyl oxidase inhibitors - Google Patents
Lysyl oxidase inhibitors Download PDFInfo
- Publication number
- CA3076566A1 CA3076566A1 CA3076566A CA3076566A CA3076566A1 CA 3076566 A1 CA3076566 A1 CA 3076566A1 CA 3076566 A CA3076566 A CA 3076566A CA 3076566 A CA3076566 A CA 3076566A CA 3076566 A1 CA3076566 A1 CA 3076566A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- compound
- cancer
- alkyl
- lox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1716871.7A GB201716871D0 (en) | 2017-10-13 | 2017-10-13 | Compounds |
| GB1716871.7 | 2017-10-13 | ||
| PCT/GB2018/052934 WO2019073251A1 (en) | 2017-10-13 | 2018-10-12 | INHIBITORS OF LYSYL OXIDASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3076566A1 true CA3076566A1 (en) | 2019-04-18 |
Family
ID=60419229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3076566A Pending CA3076566A1 (en) | 2017-10-13 | 2018-10-12 | Lysyl oxidase inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11325915B2 (https=) |
| EP (1) | EP3694857A1 (https=) |
| JP (1) | JP7385561B2 (https=) |
| CN (1) | CN111212836B (https=) |
| CA (1) | CA3076566A1 (https=) |
| GB (1) | GB201716871D0 (https=) |
| IL (1) | IL273727B2 (https=) |
| WO (1) | WO2019073251A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| CN112533897B (zh) | 2018-08-03 | 2023-07-14 | 法玛西斯有限公司 | 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途 |
| GB201818750D0 (en) * | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| AU2020317374A1 (en) * | 2019-07-25 | 2022-02-03 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| US12578335B2 (en) | 2020-02-05 | 2026-03-17 | Syntara Limited | Bioprobes for lysyl oxidases and uses thereof |
| US20230310445A1 (en) * | 2020-04-21 | 2023-10-05 | Anovia Biosciences, Inc. | Lox enzyme inhibiting methods and compositions |
| US12233056B2 (en) | 2022-04-06 | 2025-02-25 | Syntara Limited | Lysyl oxidase inhibitors for treating myeloid malignancies |
| CN116763899B (zh) * | 2023-07-17 | 2026-02-24 | 大连医科大学附属第一医院 | Htra1抑制剂在制备治疗胰腺炎-癌转化的药物中的应用 |
| CN119732928B (zh) * | 2024-12-26 | 2026-04-07 | 国家纳米科学中心 | 一种抑制胶原纤维形成的药物分子及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4992546A (en) | 1987-07-31 | 1991-02-12 | Warner-Lambert Company | Process for preparing 6,8-diazabicyclo[3.2.2]nonane derivatives |
| DE4402933A1 (de) | 1994-02-01 | 1995-08-03 | Kali Chemie Pharma Gmbh | Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel |
| CA2657623A1 (en) * | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
| BRPI0821676A2 (pt) | 2007-12-21 | 2015-06-16 | Astrazeneca Ab | Composto, composição farmacêutica, e, processo para a preparação dos compostos. |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| WO2011119345A2 (en) | 2010-03-25 | 2011-09-29 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2014348518B2 (en) * | 2013-11-14 | 2019-01-03 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9994570B2 (en) | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
| EP3267996B1 (en) * | 2015-03-12 | 2020-11-11 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| EP3317258A4 (en) * | 2015-07-01 | 2019-06-26 | Pharmakea, Inc. | LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF |
| ES2880766T3 (es) | 2016-02-09 | 2021-11-25 | Pharmakea Inc | Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos |
| JP6849197B2 (ja) | 2016-02-12 | 2021-03-24 | ファーマクシス リミテッド | リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用 |
| GB201602934D0 (en) | 2016-02-19 | 2016-04-06 | Cancer Res Inst Royal | Compounds |
| US20210009551A1 (en) | 2016-06-02 | 2021-01-14 | The Regents Of The University Of California | Compounds and methods for treating fibrosis or cancer |
| WO2018048928A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Chemical probes of lysyl oxidase-like 2 and uses thereof |
| WO2018048930A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
| US20200069648A1 (en) | 2017-03-02 | 2020-03-05 | Pharmaxis Ltd. | Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
-
2017
- 2017-10-13 GB GBGB1716871.7A patent/GB201716871D0/en not_active Ceased
-
2018
- 2018-10-12 CN CN201880065806.5A patent/CN111212836B/zh active Active
- 2018-10-12 WO PCT/GB2018/052934 patent/WO2019073251A1/en not_active Ceased
- 2018-10-12 EP EP18792450.1A patent/EP3694857A1/en active Pending
- 2018-10-12 US US16/755,739 patent/US11325915B2/en active Active
- 2018-10-12 JP JP2020520592A patent/JP7385561B2/ja active Active
- 2018-10-12 CA CA3076566A patent/CA3076566A1/en active Pending
-
2020
- 2020-03-31 IL IL273727A patent/IL273727B2/en unknown
-
2022
- 2022-04-04 US US17/712,541 patent/US12060360B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111212836B (zh) | 2023-12-15 |
| US20200331922A1 (en) | 2020-10-22 |
| EP3694857A1 (en) | 2020-08-19 |
| GB201716871D0 (en) | 2017-11-29 |
| US12060360B2 (en) | 2024-08-13 |
| US11325915B2 (en) | 2022-05-10 |
| US20220289757A1 (en) | 2022-09-15 |
| WO2019073251A1 (en) | 2019-04-18 |
| JP2020536924A (ja) | 2020-12-17 |
| IL273727B2 (en) | 2023-06-01 |
| CN111212836A (zh) | 2020-05-29 |
| JP7385561B2 (ja) | 2023-11-22 |
| IL273727A (en) | 2020-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060360B2 (en) | Lysyl oxidase inhibitors | |
| KR20240004960A (ko) | Ras 억제제 | |
| JP7601762B2 (ja) | Ｌｏｘ阻害剤 | |
| JP2025037925A (ja) | 協同的結合に関与する化合物及びその使用 | |
| CN117715658A (zh) | 抑制ras的方法 | |
| US12018029B2 (en) | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | |
| CN117529476A (zh) | 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途 | |
| CA3119882A1 (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
| JP2022507559A (ja) | Ａｍ２受容体阻害剤としての複素環スピロ化合物 | |
| WO2024003557A1 (en) | Sulfoximines as inhibitors of lysyl oxidase | |
| CN120359224A (zh) | 取代的杂环化合物衍生物及其制药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231006 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241014 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241014 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241014 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241029 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250228 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251125 |